



ASX / Media Release

20 November 2025

Deferral of AGM

Invex Therapeutics Limited (**Invex**, **ASX:IXC**, or **the Company**) announces that it has applied to the Australian Securities and Investments Commission (**ASIC**) for an extension of time to hold the Company's 2025 Annual General Meeting (**AGM**).

On 20 November 2025, ASIC extended the period within which the Company must hold its AGM from 30 November 2025 to 28 February 2026. Accordingly, the AGM which was previously scheduled for 25 November 2025 is cancelled.

Background to Deferral

On 18 September 2025, the Company announced it had received notices under sections 203D(2) and 249D of the *Corporations Act 2001* (Cth) from Celtic Capital Pte Ltd <Investment 1 A/C> to remove Dr Thomas Duthy and Mr David McAuliffe as directors of the Company. A general meeting of shareholders was subsequently scheduled to occur on 10 November 2025 to vote on the removal of Dr Duthy and Mr McAuliffe (**Requisitioned Meeting**).

On 24 October 2025, the Company issued a notice of meeting to hold its AGM on 25 November 2025. Resolution 2 was to consider the re-election of Dr Duthy for the purposes of clause 15.2 of the Company's Constitution.

On 7 November 2025, the Company announced that Dr Duthy and Mr McAuliffe had resigned as directors and the Requisitioned Meeting was cancelled.

On 10 November 2025, the Company announced that Mr Simon Owen and Professor Warren Harding AM had been appointed as non-executive directors of the Company.

As contemplated by Listing Rule 14.4 and clause 15.4 of the Company's Constitution, a director appointed to fill a casual vacancy or as an addition to the Board (other than a managing director) must not hold office, without re-election, past the next annual general meeting of the Company.

As the resolution for Dr Duthy to retire and be re-elected is no longer applicable, for the purposes of clause 15.2 of the Company's Constitution, Mr David Wheeler is to retire by rotation and be considered for re-election.

The Company considered it appropriate for the AGM scheduled for 25 November 2025 to be cancelled, and a new notice of meeting to be issued to shareholders including the resolutions relating to the re-election of Mr Wheeler, and election of Mr Owen and Professor Harding AM.

Accordingly, the Company applied to ASIC for an extension of time to hold its AGM.

New notice of meeting

The Company will issue a new Notice of Meeting in due course.

- ENDS -

This release dated 20 November 2025 has been authorised for lodgement to ASX by the Board of Invex Therapeutics Ltd.

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.